AbbVie同意降低医疗援助药品价格,在美国药店投资100B美元,以换取关税和价格豁免。 AbbVie agreed to cut Medicaid drug prices and invest $100B in U.S. pharma in exchange for tariff and pricing exemptions.

2026年1月12日, AbbVie与特朗普政府达成了一项为期三年的协议, 通过TrumpRx计划降低医疗援助计划患者的药品价格, On January 12, 2026, AbbVie struck a three-year agreement with the Trump administration to lower drug prices for Medicaid patients through the TrumpRx program, committing $100 billion over a decade to U.S. research, development, and manufacturing. 作为交换,该公司获得免除关税和未来定价任务的豁免。 In exchange, the company received exemptions from tariffs and future pricing mandates. 根据与Roche、Merck和Gilead达成的类似协议,这项交易是减少处方药成本的更广泛行政努力的一部分,尽管大多数被保险的美国人可能因保险范围依赖清单价格而看不到直接好处。 The deal is part of a broader administration effort to reduce prescription drug costs, following similar agreements with Roche, Merck, and Gilead, though most insured Americans may not see direct benefits due to reliance on list prices for insurance coverage. 具体术语尚未披露。 Specific terms remain undisclosed.